We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $2.05B
1-Year Est. Return 161.37%
This Fund
S&P 500
This Quarter Est. Return
+4.87%
1 Year Est. Return
+161.37%
3 Year Est. Return
+342.48%
5 Year Est. Return
+531.16%
10 Year Est. Return
+6,258.71%
AUM
$1.7B
AUM Growth
-$254M
Cap. Flow
-$154M
Cap. Flow %
-9.05%
Top 10 Hldgs %
40.6%
Holding
107
New
9
Increased
39
Reduced
24
Closed
7

Top Buys

Rank Stock Value
1
MMED
MiniMed Group Inc
MMED
+$17.4M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$15M
3
BSX icon
Boston Scientific
BSX
+$9.3M
4
HTFL
Heartflow Inc
HTFL
+$8M
5
PTCT icon
PTC Therapeutics
PTCT
+$7.08M

Top Sells

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$61.1M
2
CDTX
Cidara Therapeutics
CDTX
+$45.3M
3
FOLD
Amicus Therapeutics
FOLD
+$27.4M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$24M
5
TVTX icon
Travere Therapeutics
TVTX
+$21.9M

Sector Composition

Rank Sector Weight
1 Healthcare 99.77%
2 Miscellaneous 0.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VERA icon
26
Vera Therapeutics
VERA
$2.46B
$20.3M 1.19%
503,585
-64,994
-11% -$2.8M
NBIX icon
27
Neurocrine Biosciences
NBIX
$15.7B
$19.8M 1.17%
150,450
+24,950
+20% +$3.31M
ACLX
28
DELISTED
Arcellx
ACLX
$19.5M 1.15%
169,859
– –
NAMS icon
29
NewAmsterdam Pharma
NAMS
$3.1B
$18.8M 1.11%
588,794
+31,600
+6% +$1.03M
PHVS icon
30
Pharvaris
PHVS
$2.48B
$18.2M 1.07%
645,533
+22,131
+4% +$591K
ERAS icon
31
Erasca
ERAS
$6.31B
$17.9M 1.05%
1,103,469
+151,759
+16% +$1.79M
DYN icon
32
Dyne Therapeutics
DYN
$4.68B
$17.6M 1.04%
972,198
+59,243
+6% +$1.02M
CMPX icon
33
Compass Therapeutics
CMPX
$432M
$17.5M 1.03%
3,305,308
-621,894
-16% -$3.59M
ACRS icon
34
Aclaris Therapeutics
ACRS
$885M
$16.8M 0.99%
4,472,650
+18,909
+0.4% +$63.8K
TARS icon
35
Tarsus Pharmaceuticals
TARS
$3.15B
$15.8M 0.93%
225,179
-35,165
-14% -$2.46M
MMED
36
MiniMed Group Inc
MMED
$5.66B
$15.7M 0.93%
+1,055,000
New +$17.4M
ZLAB icon
37
Zai Lab
ZLAB
$2.93B
$15.3M 0.9%
814,707
+3,161
+0.4% +$58.6K
UNH icon
38
UnitedHealth
UNH
$353B
$14.3M 0.85%
53,000
+12,200
+30% +$3.63M
CNTA
39
DELISTED
Centessa Pharmaceuticals
CNTA
$14M 0.82%
351,828
+27,813
+9% +$711K
HTFL
40
Heartflow Inc
HTFL
$4.15B
$13.9M 0.82%
572,500
+294,800
+106% +$8M
ARDX icon
41
Ardelyx
ARDX
$984M
$13.8M 0.81%
2,299,473
– –
SMMT icon
42
Summit Therapeutics
SMMT
$11B
$13.5M 0.79%
710,000
– –
AZTA icon
43
Azenta
AZTA
$1.44B
$12M 0.71%
569,100
– –
MLYS icon
44
Mineralys Therapeutics
MLYS
$2.26B
$11.9M 0.7%
439,751
+12,155
+3% +$356K
DHR icon
45
Danaher
DHR
$152B
$11.7M 0.69%
61,500
– –
PTCT icon
46
PTC Therapeutics
PTCT
$5.85B
$11M 0.65%
161,798
+99,919
+161% +$7.08M
CAI
47
Caris Life Sciences
CAI
$7.24B
$10.1M 0.59%
563,000
-124,500
-18% -$2.72M
ZBIO
48
Zenas BioPharma
ZBIO
$2.04B
$9.82M 0.58%
502,077
– –
BCAX
49
Bicara Therapeutics
BCAX
$1.55B
$9.73M 0.57%
489,095
+60,000
+14% +$1.03M
BBIO icon
50
BridgeBio Pharma
BBIO
$15B
$9.52M 0.56%
128,250
+24,750
+24% +$1.79M
1
2
3 4 5

Similar funds

ABI
Abrams Bison Investments Bethesda, Maryland $2.05B AUM 71.03% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
JCM
Jacobi Capital Management Pittston, Pennsylvania $2.04B AUM 26.26% 1-Year Est. Return

Rock Springs Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Rock Springs Capital Management held 107 positions worth $1.7B, down 13% from $1.95B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Rock Springs Capital Management withdrew a net $154M in Q1 2026, closing 7 positions and reducing 24 holdings. Its most notable exit was Exact Sciences, an estimated $61.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Miscellaneous.

Against the trend, Rock Springs Capital Management opened a new position in MiniMed Group Inc worth $15.7M.

  • Rock Springs Capital Management's largest Q1 2026 buy was MiniMed Group Inc: 1,055,000 shares worth $15.7M.
  • Rock Springs Capital Management added most to Madrigal Pharmaceuticals in Q1 2026, an estimated $15M increase.
  • Rock Springs Capital Management's biggest Q1 2026 reduction was Amicus Therapeutics, cutting an estimated $27.4M.
  • Rock Springs Capital Management fully exited Exact Sciences in Q1 2026, selling an estimated $61.1M.
  • Rock Springs Capital Management's ten largest holdings make up 41% of its $1.7B portfolio in Q1 2026.
  • Rock Springs Capital Management opened 9 new positions and closed 7 in Q1 2026.
  • Rock Springs Capital Management's portfolio value fell 13% quarter-over-quarter to $1.7B.

Based on Rock Springs Capital Management's 13F filing for Q1 2026, filed 15 May 2026.